The risk or severity of adverse effects can be increased when Olanzapine is combined with Carbinoxamine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Benzocaine. The metabolism of Olanzapine can be decreased when combined with Imipramine. The risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Ethanol. The risk or severity of adverse effects can be increased when Mesoridazine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Aripiprazole. The risk or severity of adverse effects can be increased when Olanzapine is combined with Piritramide. Olanzapine may increase the sedative activities of Rotigotine. Olanzapine may decrease the stimulatory activities of Lisdexamfetamine. The therapeutic efficacy of Metformin can be decreased when used in combination with Olanzapine. The serum concentration of Fluvastatin can be increased when it is combined with Olanzapine. The therapeutic efficacy of Buformin can be decreased when used in combination with Olanzapine. Safrazine may increase the serotonergic activities of Olanzapine. Olanzapine can cause an increase in the absorption of Dexmethylphenidate resulting in an increased serum concentration and potentially a worsening of adverse effects. The metabolism of Olanzapine can be decreased when combined with Manidipine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alfaxalone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Methylphenobarbital. The risk or severity of adverse effects can be increased when Olanzapine is combined with Isoflurane. The serum concentration of Indinavir can be decreased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Ciprofloxacin. The therapeutic efficacy of Gliclazide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levocetirizine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dihydroetorphine. The risk or severity of adverse effects can be increased when Lormetazepam is combined with Olanzapine. The therapeutic efficacy of Repaglinide can be decreased when used in combination with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Vortioxetine. Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Codeine is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levetiracetam. Buspirone may increase the serotonergic activities of Olanzapine. Olanzapine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine. The therapeutic efficacy of Glipizide can be decreased when used in combination with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gepirone. Olanzapine may increase the QTc-prolonging activities of Amiodarone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Maprotiline. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chlorprothixene. Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amitriptyline. The risk or severity of adverse effects can be increased when Sumatriptan is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Osanetant. The risk or severity of adverse effects can be increased when Olanzapine is combined with Molindone. Olanzapine may decrease the stimulatory activities of Methamphetamine. The serum concentration of Rilpivirine can be increased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Dolasetron. Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Butalbital. The metabolism of Olanzapine can be decreased when combined with Nevirapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Bupivacaine. The therapeutic efficacy of Saxagliptin can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Methadone. The risk or severity of adverse effects can be increased when Moricizine is combined with Olanzapine. Benmoxin may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Tramadol is combined with Olanzapine. The serum concentration of Atazanavir can be decreased when it is combined with Olanzapine. The therapeutic efficacy of Liraglutide can be decreased when used in combination with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Pentamidine. Olanzapine can cause a decrease in the absorption of Iron saccharate resulting in a reduced serum concentration and potentially a decrease in efficacy. Olanzapine may increase the sedative activities of Pramipexole. Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. The risk or severity of adverse effects can be increased when Thioproperazine is combined with Olanzapine. The serum concentration of Olanzapine can be decreased when it is combined with Cyproterone acetate. Olanzapine may increase the QTc-prolonging activities of Gemifloxacin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Gamma Hydroxybutyric Acid. The risk or severity of adverse effects can be increased when Olanzapine is combined with Ketazolam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Difenoxin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Doxepin. Olanzapine may increase the QTc-prolonging activities of Goserelin. The risk or severity of adverse effects can be increased when Olanzapine is combined with DPDPE. The risk or severity of adverse effects can be increased when Acepromazine is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Quetiapine. Olanzapine may increase the QTc-prolonging activities of Erythromycin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Alphacetylmethadol. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. The metabolism of Olanzapine can be decreased when combined with Darifenacin. The risk or severity of adverse effects can be increased when Olanzapine is combined with Dextromoramide. The risk or severity of adverse effects can be increased when Olanzapine is combined with Tiagabine. The serum concentration of Gefitinib can be decreased when it is combined with Olanzapine. The therapeutic efficacy of AICA ribonucleotide can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Articaine. The risk or severity of adverse effects can be increased when Triazolam is combined with Olanzapine. Olanzapine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. Toloxatone may increase the serotonergic activities of Olanzapine. The serum concentration of Olanzapine can be increased when it is combined with Ranolazine. Olanzapine may increase the arrhythmogenic activities of Mequitazine. The serum concentration of Fosamprenavir can be decreased when it is combined with Olanzapine. Olanzapine may increase the QTc-prolonging activities of Pimozide. The metabolism of Olanzapine can be decreased when combined with Midostaurin. The therapeutic efficacy of Acarbose can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Olanzapine. The serum concentration of Lovastatin can be increased when it is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Diphenoxylate. The risk or severity of adverse effects can be increased when Nicergoline is combined with Olanzapine. Alaproclate may increase the serotonergic activities of Olanzapine. Olanzapine may increase the QTc-prolonging activities of Zuclopenthixol. Olanzapine may increase the QTc-prolonging activities of Iloperidone. The therapeutic efficacy of Vildagliptin can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Piribedil can be decreased when used in combination with Olanzapine. The metabolism of Olanzapine can be decreased when combined with Terbinafine. Olanzapine may increase the QTc-prolonging activities of Procainamide. The therapeutic efficacy of Miglitol can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Amobarbital. The risk or severity of adverse effects can be increased when Methylene blue is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Chloroprocaine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Pramocaine. The metabolism of Olanzapine can be decreased when combined with Cholecalciferol. The risk or severity of adverse effects can be increased when Estazolam is combined with Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Brotizolam. The risk or severity of adverse effects can be increased when Olanzapine is combined with Trazodone. The therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Olanzapine. The therapeutic efficacy of Sulodexide can be decreased when used in combination with Olanzapine. The risk or severity of adverse effects can be increased when Promethazine is combined with Olanzapine. Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine. Caroxazone may increase the serotonergic activities of Olanzapine. The risk or severity of adverse effects can be increased when Olanzapine is combined with Levomethadyl Acetate. Olanzapine may decrease the stimulatory activities of Diethylpropion. The metabolism of Olanzapine can be decreased when combined with Clomipramine. The metabolism of Olanzapine can be decreased when combined with Atomoxetine. The therapeutic efficacy of Glyburide can be decreased when used in combination with Olanzapine. The serum concentration of Olanzapine can be increased when it is combined with Abiraterone. The risk or severity of adverse effects can be increased when Olanzapine is combined with Glutethimide. The risk or severity of adverse effects can be increased when Etizolam is combined with Olanzapine. Olanzapine can cause a decrease in the absorption of Cefuroxime resulting in a reduced serum concentration and potentially a decrease in efficacy. The serum concentration of Ibrutinib can be increased when it is combined with Olanzapine. Olanzapine may decrease the stimulatory activities of Hydroxyamphetamine. Olanzapine may decrease the stimulatory activities of Dextroamphetamine. Olanzapine may increase the QTc-prolonging activities of Escitalopram.